COLUMBA Efficacy

DARZALEX FASPRO® demonstrated efficacy consistent with DARZALEX®

In the COLUMBA trial, the co-primary endpoint was achieved:
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) was non-inferior to
DARZALEX® (daratumumab) with regard to overall response rate (ORR).1

Overall response rate for DARZALEX FASPRO® vs DARZALEX®

*DARZALEX FASPRO® (95% CI: 35, 47).

DARZALEX® (95% CI: 31, 43).

The co-primary endpoint of remaining therapeutic drug concentration (maximum Ctrough) of DARZALEX FASPRO® was also non-inferior to DARZALEX®.1

CI=confidence interval; CR=complete response; Ctrough=trough concentration; ORR=overall response rate; PR=partial response; VGPR=very good partial response.

See more evidence that further supports the use of DARZALEX FASPRO® across multiple regimens in earlier lines of multiple myeloma treatment